Multi-color Mapping of Cancer Molecular Signatures and Tumor microenvironment

癌症分子特征和肿瘤微环境的多色绘图

• 批准号: 10169065
• 负责人: Jenny J. Yang
• 金额: $ 8.09万
• 依托单位: GEORGIA STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-18 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10169065
• 关键词: 2019-nCoV; Acute; Address; Advanced Development; Animal Model; Atlas of Cancer Mortality in the United States; Binding; Biological Markers; Biology; Biopsy; COVID-19; Cancer Patient; China; Chronic; Clinical; Collagen; Color; Contrast Media; Coronavirus Infections; Data; Detection; Development; Diagnosis; Diagnostic; Diagnostic Imaging; Disease; Disease Outbreaks; Disease Progression; Early Diagnosis; Exhibits; Fibrosis; Funding; Future; Goals; Heart; High Resolution Computed Tomography; Hospitals; Image; Impairment; Infection; Injury; Ionizing radiation; Lung; Lung Neoplasms; Lung diseases; Lung infections; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of lung; Medical; Metals; Metastatic Neoplasm to the Lung; Methodology; Molecular; Mus; Names; Neoplasm Metastasis; Non-Invasive Cancer Detection; Organ; Oxygen; Patients; Pattern; Penetration; Pharmaceutical Preparations; Pneumonia; Property; Proteins; Pulmonary Fibrosis; Radiation Tolerance; Radiologic Finding; Relaxation; Resolution; SARS coronavirus; Sampling Errors; Satellite Viruses; Sensitivity and Specificity; Severe Acute Respiratory Syndrome; Specificity; Staging; Symptoms; Thoracic Radiography; Tissues; Tumor stage; Validation; Viral; Virus; Virus Diseases; Virus-like particle; X-Ray Computed Tomography; base; cancer heterogeneity; chest computed tomography; density; design; effective therapy; high risk; imaging capabilities; imaging modality; imaging platform; improved; in vivo; in vivo imaging; lung imaging; molecular marker; mouse model; non-invasive imaging; novel; novel coronavirus; pandemic disease; patient stratification; prevent; quantitative imaging; respiratory; response; targeted treatment; treatment strategy; tumor microenvironment; tumor molecular fingerprint; viral detection; viral transmission

Abstract Since the recent identification of a novel coronavirus from the pneumonia outbreak in Wuhan, China, now named as SARS-CoV-2, the virus has spread globally very rapidly. SARS-CoV-2 is closely related to SARS-CoV emerged in 2003. While there are many factors associated the virus transmission, the pattern of SARS-CoV-2 spread is distinctly different from that of SARS-CoV. Evidence shows that there is virus transmission before onset of symptoms in patients. Diagnosis of the virus infection is more difficult because the infection of SARS- CoV-2 may be in the lower respiratory track. This proposal takes advantage of our pioneered imaging platform and protein agents to rapid develop pMRI diagnostic imaging with strong translational potential in facilitating effective treatment to halt further chronic and pandemic lung disease progression. It is highly transformative and specifically address the call of proposal for Urgent Supplement using existing imaging modality and MRI and largely extended its capability. The developed MRI diagnostic imaging with its high resolution, non-radiative, and much improved sensitivity than current CT in clinical will significantly facilitate accurate detection of coronavirus infection in patient and control of Covid-19 and other SARS-like COV infections.

抽象的 自从最近在中国武汉爆发的肺炎疫情中发现了一种新型冠状病毒，现将其命名为 作为 SARS-CoV-2，该病毒已在全球范围内迅速传播。 SARS-CoV-2 与 SARS-CoV 密切相关 2003 年出现。虽然病毒传播有很多因素，但 SARS-CoV-2 的模式 其传播方式与 SARS-CoV 明显不同。有证据表明之前就存在病毒传播 患者出现症状。由于SARS的感染，病毒感染的诊断更加困难 CoV-2 可能位于下呼吸道。该提案利用了我们领先的成像平台 和蛋白质制剂，以快速开发 pMRI 诊断成像，具有强大的转化潜力，可促进 有效的治疗方法可以阻止慢性和大流行性肺部疾病的进一步进展。它具有高度的变革性和 特别针对使用现有成像模式和 MRI 的紧急补充提案的号召， 很大程度上扩展了它的能力。核磁共振成像（MRI）诊断成像技术具有高分辨率、无辐射、 临床灵敏度比现有CT大幅提高，将显着促进冠状病毒的准确检测 患者感染以及 Covid-19 和其他 SARS 样 COV 感染的控制。